Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism

• Published in: Pharmacotherapy Vol. 40; no. 3; p. 204
• Main Authors: Coons, James C, Albert, Lauren, Bejjani, Andrea, Iasella, Carlo J
• Format: Journal Article
• Language: English
• Published: United States 01.03.2020
• Subjects: Administration, Oral; Aged; Anticoagulants - administration & dosage; Anticoagulants - adverse effects; Cohort Studies; Dabigatran - administration & dosage; Dabigatran - adverse effects; Female; Humans; Male; Middle Aged; Obesity, Morbid; Pulmonary Embolism - drug therapy; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Pyridones - administration & dosage; Pyridones - adverse effects; Retrospective Studies; Rivaroxaban - administration & dosage; Rivaroxaban - adverse effects; Treatment Outcome; Venous Thromboembolism - drug therapy; Warfarin - administration & dosage; Warfarin - adverse effects; venous thromboembolism; direct oral anticoagulant; obesity; anticoagulation
• ISSN: 1875-9114
• DOI: 10.1002/phar.2369

Studies on the use of direct oral anticoagulants (DOACs) in obese patients are limited. Current guidelines advise against DOAC use in patients with a body weight more than 120 kg or body mass index higher than 40 kg/m . Therefore, the aim of this study was to evaluate the effectiveness and safety of DOACs versus warfarin for the treatment of acute venous thromboembolism (VTE) in obese patients. Retrospective matched cohort study. Integrated delivery system of 40 academic, community, and specialty hospitals. A total of 1840 adults with a primary admission diagnosis of acute VTE who received a DOAC (apixaban, dabigatran, or rivaroxaban [632 patients] or warfarin [1208 patients]) while hospitalized between January 1, 2011, and October 1, 2015, and who had a body weight more than 100 kg and less than 300 kg, were included. Patients in the warfarin group were matched in a 2:1 ratio to patients who received a DOAC based on history of VTE, chronic kidney disease, race, and age. The primary outcome was recurrence of VTE within 12 months of the index admission date. Secondary outcomes included occurrence of pulmonary embolism (PE) and deep vein thrombosis (DVT) events separately within the study time frame, as well as bleeding within 12 months of the index admission date. No significant difference in the recurrence of VTE was observed between patients who received a DOAC compared with those who received warfarin (6.5% vs 6.4%, p=0.93). Likewise, no significant differences in the occurrence of PE and DVT were seen between the DOAC- and warfarin-treated patients (3.7% vs 3.8%, p=0.94, and 3% vs 3.5%, p=0.56, respectively). Bleeding occurred in 1.7% and 1.2% of patients in the DOAC and warfarin groups, respectively (p=0.31). To our knowledge, this is the largest clinical study to date showing that patients with obesity can be treated effectively and safely with a DOAC compared with warfarin for acute VTE. Thus DOACs should be considered a reasonable alternative to warfarin for treatment of acute VTE in obese patients.